Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases
Zenas will receive a $50 million up-front cash payment and an equity investment from Bristol Myers Squibb, along with additional potential milestone-based payments and royalties in the licensed territory
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced that it has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia.
Obexelimab is an investigational bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and FcγRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. Obexelimab is currently being studied as a subcutaneous injection in a global Phase III trial in patients with IgG4-Related Disease (IgG4-RD), a disease for which there are currently no approved treatments. The compound is also being studied in a global Phase II/III trial in patients with warm antibody Auto-Immune Hemolytic Anemia (wAIHA).
“This collaboration marks an important step forward in realizing our vision for obexelimab to benefit patients living with auto immune diseases globally,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “The deeply experienced and passionate team at Bristol Myers Squibb is an ideal partner based on their proven development, regulatory and commercial capabilities in Japan and throughout the licensed territory.”
“This collaboration represents an important opportunity to address unmet needs for people living with IgG4-RD, for which there are no approved treatment options,” said Steve Sugino, Senior Vice President & General Manager, Japan, Bristol Myers Squibb. “We are excited to work with Zenas BioPharma to expand the reach of obexelimab in the licensed territory and to make an impact on the lives of patients that are waiting.”
Under the terms of the license agreement, Zenas will receive a $50 million up-front cash payment and is eligible to receive additional payments in connection with the achievement of certain development, regulatory and commercial milestones, as well as royalties on net sales of obexelimab in the licensed territory. In exchange, Bristol Myers Squibb will receive exclusive rights to develop and commercialize obexelimab in the licensed territory. In addition, Bristol Myers Squibb is making an equity investment in Zenas.
Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.
More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 3 (SApHiAre) study is available at clinicaltrials.gov: NCT05786573.
About IgG4-related disease
IgG4-RD is a chronic, immune-mediated fibro-inflammatory disease that can affect multiple organs including the major salivary glands, orbits, lacrimal glands, pancreas, biliary tree, lungs, kidneys, and retroperitoneum. Approximately 20,000 patients are diagnosed with IgG4-RD in the United States alone. Despite its increasing recognition, there remains a need for further research and effective therapeutic options for individuals living with this debilitating disease.
Across the world, the use of glucocorticoids is widely considered to be the standard of care for treating IgG4-RD. There are no approved treatment options for this condition. While commonly used, glucocorticoids and available B cell depleting therapies rarely lead to long-term, treatment-free remissions, and are associated with a high risk of toxicity in these patients. Such therapies may also impair vaccine responses, including those for SARS-CoV-2 and influenza.
About Zenas BioPharma
Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.
Investor and Media Contact:
Joe Farmer, President & COO
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Technicolor Creative Studios: Business Update and First Half 2023 Financial Results2.10.2023 21:55:38 CEST | Press release
CORPORATE PRESS RELEASE Technicolor Creative StudiosBusiness Update and First Half 2023Financial Results PARIS (FRANCE), OCTOBER 2,2023 – Technicolor Creative Studios (Euronext Paris: TCHCS) (the “Company”) today provided business update and announced its first half 2023 financial results1. Acceleration of the transformation plan to drive the recovery of the business Impact of strikes in Hollywood andunfavourable macroeconomic environment led to reduction of activity withlower financial and operational performancefor thefirst half 2023Renewed confidence from majority shareholders and lenders with:An additional €30 million of new money injection to address liquidity needs A proposed tender offer (“offre publique d’achat simplifiée”)at a price of 1,63 euro per share, dividends included,to beinitiated by a large majority of shareholders and lenders (holding 94,82% of the capital) acting in concert in view of proceeding to a mandatory squeeze outto achieve delisting of Technicolor Creative
Meltwater launches new mChampion program in the Meltwater Customer Community2.10.2023 21:39:09 CEST | Press release
SAN FRANCISCO, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Meltwater, a leading global provider of social, media and consumer intelligence, today announces the launch of its new mChampions Community Rewards Program to enhance customer experience and provide career elevation and networking opportunities, in the Meltwater Customer Community. Meltwater’s Customer Community, mCommunity, is an online, self-service community for Meltwater customers to share knowledge, challenges, best practices and experiences to build skills and advance their careers in PR, Communications and Marketing. With over 7,000 members and several community-led discussion boards and groups established, mCommunity has created an environment where users can collaborate and succeed together. Today, through Meltwater’s customer-centric approach and commitment to fostering knowledge sharing through mCommunity, Meltwater has taken a significant leap forward with the introduction of the mChampions program – a rewards program exclusi
SKEL fjárfestingafélag hf.: Buy-back programme week 392.10.2023 20:04:24 CEST | Press release
In week 39 2023, SKEL fjárfestingafélag hf. purchased in total 7,350,000 own shares for total amount of 96,345,000 ISK as follows: DateTimePurchased sharesPricePurchase priceTotal own shares25.9.202309:35:00 500,000 13.30 6,650,000 27,118,518 25.9.202310:25:00 500,000 13.25 6,625,000 27,618,518 25.9.202314:49:00 500,000 13.30 6,650,000 28,118,518 25.9.202314:50:00 500,000 13.30 6.650.000 28,618,518 26.9.202309:53:00 500,000 13.40 6.700.000 29,118,518 26.9.202310:08:00 500,000 13.40 6.700.000 29,618,518 26.9.202312:49:00 500,000 13.25 6.625.000 30,118,518 26.9.202314:14:00 500,000 13.20 6.600.000 30,618,518 27.9.202310:04:00 500,000 12.90 6.450.000 31,118,518 27.9.202312:54:00 500,000 12.85 6.425.000 31,618,518 27.9.202314:21:00 450,000 12.85 5.782.500 32,068,518 27.9.202315:29:00 450,000 12.85 5.782.500 32,518,518 28.9.202310:01:00 450,000 12.90 5.805.000 32,968,518 28.9.202315:06:00 1,000,000 12.90 12.900.000 33,968,518 7,350,00096,345,00033,968,518 The execution of the buy-back progr
Nokia Corporation: Repurchase of own shares on 02.10.20232.10.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 2 October 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 02.10.2023 Espoo, Finland – On 2 October 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL341,8703.53CEUX35,2183.53AQEU1,5003.53TQEX22,4123.56Total401,0003.53 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023
Iceland Seafood International hf: Completes auction of bills2.10.2023 19:06:52 CEST | Press release
Iceland Seafood International hf. has concluded an offering of 3-month bills in the new series ICESEA 24 0105. Total offers for bills in the auction amounted to ISK 1.560 million and offers were accepted for ISK 1.300 million, at a simple rate of 11.75%. The bills are scheduled to be admitted to trading on Nasdaq Iceland in the coming weeks.